Zanamivir

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 2: Line 2:
{| class="wikitable" border="1" width="52%" style="text-align:center"
{| class="wikitable" border="1" width="52%" style="text-align:center"
|-
|-
-
! colspan="12" align="center"| Neuraminidase Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir (RELENZA™) 10mg Administered Twice Daily for 5 Days by Rotacap/Rotahaler Compared to ROTADISK™/DISKHALER™ in Healthy Subjects, Study No: NAI113625, 2009</ref>
+
! colspan="12" align="center"| Neuraminidase Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir (RELENZA™) 10mg Administered Twice Daily for 5 Days by Rotacap/Rotahaler Compared to ROTADISK™/DISKHALER™ in Healthy Subjects, Study No: NAI113625, 2009</ref><ref>DOI: 10.1007/s00228-003-0639-6</ref>
|-
|-
! Parameter
! Parameter
Line 10: Line 10:
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
! 1.25
! 1.25
-
! [[Oseltamivir]]
+
! 1.5
|-
|-
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
! 31.6
! 31.6
-
! [[Oseltamivir]]
+
! 57
|-
|-
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
! 2
! 2
-
! [[Oseltamivir]]
+
! 75
|-
|-
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
Line 26: Line 26:
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
! 3
! 3
-
! [[Oseltamivir]]
+
! 3.2
|-
|-
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
! 185
! 185
-
! [[Oseltamivir]]
+
! 204
|-
|-
! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h)
! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h)
Line 38: Line 38:
! Dosage (mg)
! Dosage (mg)
! 10
! 10
-
! [[Oseltamivir]]
+
! 300
|-
|-
! Metabolism
! Metabolism

Revision as of 15:05, 8 December 2010

Pharmacokinetics

Neuraminidase Inhibitor Pharmacokinetics[1][2]
Parameter Ritonavir Oseltamivir
Tmax (hr) 1.25 1.5
Cmax (ng/ml) 31.6 57
Bioavailability (%) 2 75
Protein Binding (%) 10 Oseltamivir
T1/2 (hr) 3 3.2
AUC (ng/ml/hr) 185 204
Clearance (L/h) 54.1 Oseltamivir
Dosage (mg) 10 300
Metabolism None Oseltamivir

Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

Personal tools